Clinical Trial Update: Enzalutamide in Patients With Androgen Receptor Positive (AR+) Ovarian, Primary Peritoneal or Fallopian Tube Cancer and One, Two or Three Prior Therapies [Phase 2]

View source ↗

Summary

Phase 2 trial update for enzalutamide in AR-positive ovarian, fallopian tube, or primary peritoneal cancer completed with results posted.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Epithelial Ovarian Cancer
• Fallopian Tube Cancer
• Peritoneal Carcinoma

Drugs mentioned

• Enzalutamide (enzalutamide)

Snippet

Sponsor: Memorial Sloan Kettering Cancer Center | Conditions: Advanced Epithelial Ovarian, Recurrent Epithelial Ovarian | Phase 2 | Status: COMPLETED | Results posted: 2023-04-28